EXCLUSIVE: It is aiming for ‘world firsts’ in the study of the plant’s medicinal benefits
Cannabinoid biotechnology company MediPen is launching its own dedicated 1,800ft sq marijuana research facility this summer, which will also provide a platform for anyone looking to utilise its facilities for the purposes of driving innovation around the use of medicinal cannabis.
The company, which has had big success selling non-psychoactive CBD vaporisers that users claim to have a long list of medicinal benefits, is currently in the process of securing a license from the Home Office to import and work with controlled compounds found in cannabis so it can study the plant in greater detail.
READ THE FULL STORY BELOW